Vertex Pharmaceuticals Purchases ACD/Labs’ Nomenclature Software
Toronto, Canada (January 10, 2007)—Scientists working for global biotechnology company Vertex Pharmaceuticals Incorporated now have a new tool, ACD/Name Batch, which allows them to quickly generate systematic names for new chemical compounds added to the company’s registry.
ACD/Name Batch generates accurate systematic names for a wide variety of diverse chemical classes according to both IUPAC nomenclature recommendations and CAS-based Index rules. Known for quality and reliability, ACD/Name Batch ensures that proper naming of a complex structure takes only a few seconds. The software can process hundreds of thousands of structures in one session in an unattended mode, and can be integrated into an existing Linux-based or other system, allowing scientists to either register compounds directly into their corporate database or receive a real-time name directly from the nomenclature software.
“The systematic nomenclature algorithms underlying ACD/Name Batch have been incrementally enhanced, year over year, for the past decade,” comments Antony Williams, VP and Chief Science Officer for ACD/Labs. “Our commitment to quality and adherence to the IUPAC nomenclature rules has helped to position ACD/Name as the solution of choice for organizations concerned with the highest quality systematic nomenclature.”
For further information on ACD/Name Batch, please visit http://www.acdlabs.com/namebatch/
About Advanced Chemistry Development
Advanced Chemistry Development, Inc., (ACD/Labs) is a chemistry software company offering solutions that truly integrate chemical structures with analytical chemistry information to produce ChemAnalytics®. ACD/Labs creates innovative software packages that aid chemical research scientists worldwide with spectroscopic validation of structures, elucidation of unknown substances, chromatographic separation, medicinal chemistry, preformulation of novel drug agents, systematic nomenclature generation, and chemical patenting and publication. Founded in 1994, and headquartered in Toronto, Canada, ACD/Labs employs a team of over 145 dedicated individuals whose continual efforts carry ACD/Labs’ innovative technologies into pharmaceutical, biotech, chemical, and materials companies throughout the world. Information about Advanced Chemistry Development and its products is available at www.acdlabs.com.
About Vertex
Vertex Pharmaceuticals Incorporated is a global biotechnology company committed to the discovery and development of breakthrough small molecule drugs for serious diseases. The Company’s strategy is to commercialize its products both independently and in collaboration with major pharmaceutical companies. Vertex’s product pipeline is focused on viral diseases, inflammation, autoimmune diseases, cancer, pain and bacterial infection. Vertex co-discovered the HIV protease inhibitor, Lexiva, with GlaxoSmithKline.
